Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers

Drug Metabolism and Disposition

Volumn 32, Issue 7, 2004, Pages 689-698

  Bu, Hai Zhi ^a   Pool, William F ^a   Wu, Ellen Y ^a   Raber, Susan R ^a   Amantea, Michael A ^a   Shetty, Bhasker V ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPRAVIRINE; DRUG METABOLITE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SULFATION; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; ION TRAP MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MALE; MULTIPLE DRUG DOSE; NORMAL HUMAN; OXYGENATION; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCHEMISTRY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANTI-HIV AGENTS; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FECES; HUMANS; IMIDAZOLES; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFUR COMPOUNDS; TIME FACTORS;

EID: 3042554700     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.32.7.689     Document Type: Article

References (18)

1. De Clercq E (2001) New developments in anti-HIV chemotherapy. Curr Med Chem 8:1543-1572.
2. De Clercq E (2002) Highlights in the development of new antiviral agents. Mini Rev Med Chem 2:163-175.
3. Fujiwara T, Sato A, el-Farrash M, Miki S, Abe K, Isaka Y, Kodama M, Wu Y, Chen LB, Harada H, et al. (1998) S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 42:1340-1345.
4. Fujiwara T, Sato A, Patick AK, and Potts KE (1999) In vitro antiviral activity and resistance profile of AG1549 (S-1153), a new non-nucleoside inhibitor of HIV-1 reverse transcriptase. Int Antiviral News 7:18-20.
5. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection, Nature (Lond) 373: 123-126.
6. Jin L, Chen I-W, Chiba M, and Lin JH (2003) Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys. Xenobiotica 33:643-654.
7. Katzenstein DA, Holodniy M, Israelski DM, Sengupta S, Mole LA, Bubp JL, and Merigan TC (1992) Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. J Acquir Immune Defic Syndr 5:107-112.
8. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, and Granneman GR (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 27:902-908.
9. Kumar GN, Rodrigues AD, Buko AM, and Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423-431.
10. Lalezari JP, Henry K, O'Hearn M, Montaner JSG, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, et al. (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175-2185.
11. McLafferty FW and Tureček F (1993) Interpretation of Mass Spectra. University Science Books, Mill Valley, CA.
12. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio-Monforte A, Yust I, Bruun JN, Phillips AN, and Lundgren JD (1998) Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 352:1725-1730.
13. Ohkawa T, Goto S, Miki S, Sato A, Kuroda T, Iwatani K, Takeuchi M, and Nakano M (1998) Structural determination of metabolites of S-1153, a new, potent, non-nucleoside, anti-HIV agent in rat liver microsomes. Xenobiotica 28:877-886.
14. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, and Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853-860.
15. Ramanathan R, Su AD, Alvarez N, Blumenkrantz N, Chowdhury SK, Alton K, and Patrick J (2000) Liquid chromatography/mass spectrometry methods for distinguishing N-oxides from hydroxylated compounds. Anal Chem 72:1352-1359.
16. Ren J, Nichols C, Bird LE, Fujiwara T, Sugimoto H, Stuart DI, and Stammers DK (2000) Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding. J Biol Chem 275:14316-14320.
17. Tong W, Chowdhury SK, Chen JC, Zhong R, Alton KB, and Patrick JE (2001) Fragmentation of N-oxides (deoxygenation) in atmospheric pressure ionization: investigation of the activation process. Rapid Commun Mass Spectrom 15:2085-2090.
18. Wei XP, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature (Lond) 373:117-122.